Cyclerion Therapeutics (CYCN) to Release Earnings on Tuesday

Cyclerion Therapeutics (NASDAQ:CYCN) is expected to be issuing its results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Cyclerion Therapeutics Trading Up 3.1%

NASDAQ:CYCN opened at $1.35 on Friday. Cyclerion Therapeutics has a 1-year low of $1.03 and a 1-year high of $3.79. The business’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.84. The firm has a market capitalization of $5.31 million, a price-to-earnings ratio of -1.80 and a beta of 0.98.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.